ALNY

Alnylam Pharmaceuticals Inc

225.10

Oct 21 • 3:59 PM ET -5.61 (-2.43%)

225.10

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Large NASD

Peers: ARWR IONS BBIO REGN ARGX VRTX WVE BMRN NTLA AMGN

| Held by: VTI VO QQQ VUG VXF VOT IBB CGGR IWP TCAF

Scroll to Statements

Index	NDX
Market Cap	30.12B
Enterprise Value	29.80B
Income	807.99M
Sales	4.80B
Book/sh	10.13
Cash/sh	24.72
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	2500
IPO	May 28, 2004

P/E	38.01
Forward P/E	23.37
PEG	0.32
P/S	6.27
P/B	22.23
P/C	9.10
P/FCF	37.94
EV/EBITDA	28.26
EV/Sales	6.20
Quick Ratio	2.99
Current Ratio	3.05
Debt/Eq	2.21
LT Debt/Eq	1.98
Option/Short	Yes / Yes

EPS (ttm)	5.92
EPS next Y	9.63
EPS next Q	1.67
EPS this Y	178.73%
EPS next Y	48.33%
EPS next 5Y	72.60%
EPS past 3/5Y	- -
Sales past 3/5Y	52.98% 49.77%
EPS Y/Y TTM	347.31%
Sales Y/Y TTM	95.14%
EPS Q/Q	337.86%
Sales Q/Q	66.86%
Earnings	Oct 29 BMO
EPS/Sales Surpr.	-25.78% -2.36%

Insider Own	0.32%
Insider Trans	-1.29%
Inst Own	100.62%
Inst Trans	-0.99%
ROA	15.96%
ROE	100.70%
ROIC	20.01%
Gross Margin	79.65%
Oper. Margin	20.81%
Profit Margin	16.82%
SMA20	-3.56%
SMA50	-5.83%
SMA200	-22.85%
Trades

Shs Outstand	133.73M
Shs Float	133.38M
Short Float	5.78%
Short Ratio	4.48
Short Interest	7.71M
52W High	490.05 -54.07%
52W Low	197.81 13.80%
Volatility	2.93% 3.74%
ATR (14)	8.85
RSI (14)	42.05
Beta	0.36
Rel Volume	0.69
Avg Volume	1.72M
Volume	1,180,951

Perf Week	0.28%
Perf Month	-10.55%
Perf Quarter	-16.24%
Perf Half Y	-27.52%
Perf YTD	-43.39%
Perf Year	-52.51%
Perf 3Y	39.13%
Perf 5Y	10.16%
Perf 10Y	513.77%
Recom	1.61
Target Price	371.39
Prev Close	230.71
Price	225.10
Change %	-2.43%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-15-26	Resumed	UBS	Buy	$354
Aug-19-26	Initiated	BMO Capital Markets	Outperform	$318
Aug-03-26	Upgrade	Raymond James	Outperform → Strong Buy	$420
May-19-26	Initiated	Citigroup	Buy	$380
Mar-16-26	Downgrade	Jefferies	Buy → Hold	$330
Jan-28-26	Resumed	Barclays	Overweight	$527
Jan-07-26	Resumed	Oppenheimer	Outperform	$500
Aug-04-25	Upgrade	Wolfe Research	Underperform → Peer Perform
Aug-04-25	Upgrade	Oppenheimer	Perform → Outperform	$490
Jul-30-25	Resumed	Raymond James	Outperform	$370
Jul-21-25	Initiated	Truist	Buy	$385
Mar-31-25	Initiated	Redburn Atlantic	Buy	$353
Mar-24-25	Upgrade	JP Morgan	Neutral → Overweight	$280 → $328
Nov-12-24	Downgrade	Wolfe Research	Peer Perform → Underperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-16-24	Upgrade	Goldman	Neutral → Buy	$198 → $370
Feb-16-24	Downgrade	Goldman	Buy → Neutral	$173
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-08-23	Initiated	Wells Fargo	Equal Weight	$171
Dec-08-23	Initiated	Wells Fargo	Equal Weight

Show Previous Ratings

Oct-21-26 09:53AM	Alnylam Must Prove First-Line Amvutra Demand Can Carry A Reset TTR Outlook (Earnings Whispers)
Oct-19-26 10:19AM	Why Merck KGaA Is Paying a 130% Premium For This Gene-Silencing Tech (Barrons.com)
Oct-18-26 11:15PM	Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In (Stocktwits)
Oct-16-26 10:44AM	What Is The Case For Waiting On Moderna Stock? (Trefis)
06:50AM	Jefferies Highlights Top Mid-Cap Biotech Stocks Ahead of Earnings (Investing.com)
06:33AM	Loading…
06:33AM	Next-gen RNAi drugmaker City prices $200M IPO (BioPharma Dive)
Oct-15-26 08:00AM	Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results (Business Wire)
Oct-12-26 05:01PM	Where Could Moderna's Next Growth Come From? (Trefis)
Oct-09-26 11:36AM	Is Vertex Stock Worth More Than Its Competitors? (Trefis)
Sep-29-26 09:00AM	AMVUTTRA (vutrisiran) 'Play by Play' Initiative Highlights Former Athletes' Stories to Shine a Light on the Often-Missed Signs of ATTR-CM (Business Wire)
Sep-24-26 08:36PM	RNAi drug specialist ADARx raises $446M IPO (BioPharma Dive)
Sep-22-26 01:39PM	Was Moderna Stock's Cancer Vaccine Run Visible In Advance? (Trefis)
Sep-15-26 11:18AM	Slate Medicines Names Kenneth Koblan as Chief Scientific Officer (Exec Edge)
Sep-02-26 08:00AM	Alnylam to Webcast Presentations at Upcoming September Investor Conferences (Business Wire) +8.65%
Aug-31-26 08:48AM	Inceptive CEO Jakob Uszkoreit on Designing Medicines That Work Like Life Itself (NYSE)
08:23AM	Loading…
Aug-30-26 08:23AM	Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings (Business Wire)
Aug-28-26 05:18PM	IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial Jefferies Sees Neutral To Negative Readthrough To ALNY (Stocktwits)
08:54AM	Alnylam stock drops on rival heart trial: Why analysts see core business safe (Investing.com)
06:58AM	AstraZeneca, Ionis data spark debate about RNA drugs impact on deadly heart disease (BioPharma Dive)
Aug-26-26 11:13AM	Moderna Stock Carries A Market Value Its Revenue Does Not Support (Trefis)
Aug-24-26 03:01PM	Moderna Stock Had A Readout Waiting In Plain Sight (Trefis)
08:33AM	Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026 (Business Wire)
Aug-20-26 02:21PM	Moderna's Melanoma Result Landed On A Market Positioned The Other Way (Trefis) -5.49%
Aug-11-26 06:21AM	Drugs that missed the mark in pharmas last earnings round (Pharma Voice)
Aug-03-26 09:49AM	Starbucks upgraded, eBay downgraded: Wall Street's top analyst calls (The Fly) +7.21%
Jul-31-26 03:29PM	Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap? (Trefis)
Jul-30-26 05:04PM	Alnylam Pharmaceuticals Inc (ALNY) (Q2 2026) Earnings Call Highlights: Amvuttra Surpasses $1 ... (GuruFocus.com) -28.31%
12:12PM	Alnylam plunges as earnings deliver one-two punch (BioPharma Dive)
08:16AM	Alnylam: Q2 Earnings Snapshot (Associated Press)
08:00AM	Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress (Business Wire)
11:00AM	Loading…
Jul-23-26 11:00AM	Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company? (Trefis)
Jul-16-26 09:06AM	Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside (Trefis)
08:00AM	Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results (Business Wire)
Jul-15-26 03:30AM	Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease (Business Wire)
Jul-13-26 09:12AM	What It Means To Hold Moderna Stock In A Crash (Trefis)
Jul-10-26 08:14AM	Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act? (Trefis)
07:35AM	The Long Climb Back For Ionis Stock (Trefis)
Jul-09-26 10:38AM	AstraZeneca, Ionis Stocks Stumble After Heart Drug Fails Key Trial (The Wall Street Journal)
07:38AM	AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars. (Barrons.com)
07:14AM	AstraZeneca stock drops 9% after Wainua heart drug trial fails (Quartz)
Jul-08-26 08:48AM	Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside (Trefis)
Jun-25-26 09:00AM	Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform (Business Wire)
Jun-12-26 09:00AM	Alnylam to Host Tenth RNAi Roundtable Webcast Series (Business Wire)
Jun-04-26 06:42AM	Alnylam, Inceptive ink AI deal potentially worth $2B (BioPharma Dive)
Jun-03-26 04:45PM	Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics (Business Wire)
May-28-26 04:27PM	JPMorgan says large-cap biotech is back as profits and pipelines fuel upside (Investing.com)
May-20-26 03:29PM	JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms (Investing.com)
May-19-26 09:34AM	StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls (The Fly)
09:33AM	Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout (Proactive)
08:30AM	Alnylam Issues 2025 Corporate Responsibility Report (Business Wire)
May-12-26 02:30AM	New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden (Business Wire)
May-07-26 08:00AM	Alnylam to Webcast Presentations at Upcoming Investor Conferences (Business Wire)
May-04-26 08:30AM	Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM (Business Wire)
Apr-30-26 04:45PM	Alnylam Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary (Moby)
09:15AM	Alnylam Pharma Surges After Sales Of Its Biggest Moneymaker Catapult (Investor's Business Daily)
08:09AM	Alnylam: Q1 Earnings Snapshot (Associated Press)
08:00AM	Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress (Business Wire)
Apr-16-26 08:00AM	Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results (Business Wire)
Apr-07-26 10:00AM	Nasdaq opens in red as Iran says 'restraint is ended' ahead of Trump deadline (Proactive)
09:49AM	FTSE 100 Live: Defence stocks lead decline as Trump's Iran deadline looms (Proactive)
Mar-30-26 01:00PM	New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management (Business Wire)
Mar-24-26 07:30AM	Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association (Business Wire)
Mar-16-26 09:37AM	Qualcomm, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Mar-10-26 02:49PM	BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz (Benzinga)
08:00AM	Alnylam to Webcast TTR Investor Webinar (Business Wire)
Mar-06-26 07:19AM	Alnylam and Tenaya sign $1.23bn cardiovascular target discovery deal (Pharmaceutical Technology)
05:13AM	Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs (BioPharma Dive)
Mar-05-26 01:35PM	Tenaya Therapeutics Stock Jumps After New Alnylam Deal (Benzinga)
Mar-04-26 06:57AM	Blackstone puts $400M into Teva, Sanofi gut disease drug (BioPharma Dive)
Mar-02-26 11:39PM	Alnylam Pharmaceuticals Touts AMVUTTRA Momentum, Teases Key Pipeline Readouts at TD Cowen Conf. (MarketBeat)
Mar-01-26 01:33AM	Canaccord Genuity Maintains Buy Rating on Alnylam Pharmaceuticals, Inc. (ALNY) Stock (Insider Monkey)
Feb-24-26 11:43AM	GSK Strikes $1 Billion China RNA Deal (GuruFocus.com)
Feb-23-26 10:00AM	Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference (Business Wire)
Feb-20-26 04:08AM	Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge (Insider Monkey)
Feb-19-26 12:01AM	Analysts Trim Alnylam Pharmaceuticals, Inc. (ALNY) Targets but Keep Faith in 2026 Growth (Insider Monkey)
Feb-17-26 12:09PM	RNA-targeting small molecules: a new frontier of drug discovery (Pharmaceutical Technology) +5.79%
Feb-14-26 01:21AM	Is Alnylam Pharmaceuticals (ALNY) One of the Best Upside Stocks to Invest In Right Now? (Insider Monkey)
Feb-13-26 04:30PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) +5.79%
10:19AM	ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down (Zacks)
Feb-12-26 04:31PM	Alnylam Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby)
04:06PM	Alnylam Pharmaceuticals Inc (ALNY) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
12:23PM	Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor (BioPharma Dive)
10:00AM	Here's What Key Metrics Tell Us About Alnylam (ALNY) Q4 Earnings (Zacks)
09:10AM	Alnylam Pharmaceuticals (ALNY) Surpasses Q4 Earnings Estimates (Zacks)
08:22AM	Alnylam: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress (Business Wire)
Feb-11-26 12:57PM	Pharma companies left out of Trump's drug-pricing deals look for way in (Reuters)
Feb-10-26 10:00AM	Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings Growth (Zacks)
Feb-09-26 09:15AM	Countdown to Alnylam (ALNY) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Feb-06-26 08:34AM	Do Options Traders Know Something About Alnylam Pharmaceuticals Stock We Don't? (Zacks)
Feb-05-26 10:00AM	Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: Should You Buy? (Zacks) -5.89%
Jan-31-26 09:35AM	Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth (Insider Monkey)
Jan-29-26 09:55PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
04:09PM	Phillip Allen Sharp Improved Human Health With Breakthroughs (Investor's Business Daily)
02:27PM	Alnylam Pharmaceuticals Projects 2026 Revenue Around $5.3 Billion as It Focuses on a New Five-Year Strategy (Insider Monkey)
08:00AM	Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Jan-28-26 05:04AM	Should You Buy Alnylam Pharmaceuticals Before Feb. 12? (Motley Fool)
Jan-27-26 08:38AM	Wells Fargo Raises Alnylam (ALNY) Revenue Estimates for Amvuttra Despite Projected Margin Compression (Insider Monkey)
Jan-14-26 08:02AM	JPM26: 2025 a breakout year for rare disease biotechs (Clinical Trials Arena)
Jan-12-26 07:03PM	Alnylam Pharmaceuticals CEO on Development Goals, Profitability (Bloomberg) -6.87%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SUPRAN BRYAN	EVP, CLO and Secretary	Oct 02 '26	Sale	226.88	1,758	398,855	12,807	Oct 06 04:12 PM
SUPRAN BRYAN	Officer	Oct 02 '26	Proposed Sale	226.88	1,758	398,862		Oct 02 03:45 PM
PYOTT DAVID E I	Director	Jun 01 '26	Option Exercise	0.00	3,830	0	5,412	Jun 03 04:25 PM
PYOTT DAVID E I	Director	Jun 01 '26	Sale	299.18	3,830	1,145,853	1,582	Jun 03 04:25 PM
PYOTT DAVID E I	Director	Jun 01 '26	Proposed Sale	299.51	3,830	1,147,123		Jun 01 04:25 PM
SCHULMAN AMY W	Director	May 13 '26	Option Exercise	70.20	11,250	789,750	23,211	May 14 04:17 PM
McLaughlin Melissa	Chief Human Resources Officer	Apr 06 '26	Sale	330.42	2,286	755,329	9,443	Apr 07 04:21 PM
McLaughlin Melissa	Chief Human Resources Officer	Apr 02 '26	Sale	319.59	1,624	519,014	11,729	Apr 07 04:21 PM
McLaughlin Melissa	Officer	Apr 06 '26	Proposed Sale	320.10	2,286	731,749		Apr 06 04:05 PM
Garg Pushkal	EVP Chief R&D	Mar 05 '26	Sale	323.96	2,404	778,812	18,693	Mar 06 04:13 PM
Garg Pushkal	EVP Chief R&D	Mar 04 '26	Sale	323.08	2,309	745,984	21,097	Mar 06 04:13 PM
Greenstreet Yvonne	Chief Executive Officer	Mar 04 '26	Sale	323.08	2,933	947,581	95,695	Mar 06 04:13 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Mar 04 '26	Sale	323.08	2,468	797,351	61,805	Mar 06 04:12 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Mar 04 '26	Sale	323.08	2,309	745,984	34,297	Mar 06 04:12 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 05 '26	Sale	323.98	658	213,177	20,569	Mar 06 04:11 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 04 '26	Sale	323.08	633	204,508	21,227	Mar 06 04:11 PM
Fitzgerald Kevin Joseph	Officer	Mar 05 '26	Proposed Sale	323.69	658	212,988		Mar 05 04:04 PM
Garg Pushkal	Officer	Mar 05 '26	Proposed Sale	323.69	2,404	778,151		Mar 05 04:03 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Mar 02 '26	Sale	327.65	2,206	722,801	64,273	Mar 04 07:31 PM
Garg Pushkal	EVP Chief R&D	Mar 03 '26	Sale	319.74	1,775	567,546	23,406	Mar 04 07:31 PM
Garg Pushkal	EVP Chief R&D	Mar 02 '26	Sale	327.66	1,717	562,585	25,181	Mar 04 07:31 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 03 '26	Sale	319.73	1,652	528,189	21,860	Mar 04 07:30 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 02 '26	Sale	327.65	1,598	523,584	23,512	Mar 04 07:30 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Mar 02 '26	Sale	327.65	1,598	523,584	36,606	Mar 04 07:30 PM
Greenstreet Yvonne	Chief Executive Officer	Mar 02 '26	Sale	327.65	6,799	2,227,698	98,628	Mar 04 07:29 PM
Fitzgerald Kevin Joseph	Officer	Mar 03 '26	Proposed Sale	321.37	1,652	530,903		Mar 03 04:49 PM
Garg Pushkal	Officer	Mar 03 '26	Proposed Sale	321.37	1,775	570,432		Mar 03 04:11 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 27 '26	Option Exercise	0.00	5,921	0	91,583	Mar 02 04:10 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 27 '26	Option Exercise	0.00	1,908	0	61,710	Mar 02 04:09 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 27 '26	Option Exercise	0.00	1,666	0	33,435	Mar 02 04:09 PM
Garg Pushkal	EVP Chief R&D	Feb 27 '26	Option Exercise	0.00	1,908	0	26,756	Mar 02 04:08 PM
Garg Pushkal	EVP Chief R&D	Feb 27 '26	Sale	331.34	4,627	1,533,100	22,129	Mar 02 04:08 PM
Garg Pushkal	Officer	Feb 27 '26	Proposed Sale	331.34	4,627	1,533,107		Feb 27 04:05 PM
Garg Pushkal	EVP Chief R&D	Feb 13 '26	Sale	310.08	2,242	695,201	24,848	Feb 17 07:28 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 13 '26	Sale	310.08	6,958	2,157,542	85,662	Feb 17 07:27 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 13 '26	Sale	310.08	1,959	607,448	31,769	Feb 17 07:27 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 17 '26	Sale	331.96	2,041	677,532	21,264	Feb 17 07:26 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 13 '26	Sale	310.08	1,959	607,448	23,305	Feb 17 07:26 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 13 '26	Sale	310.08	2,242	695,201	59,802	Feb 17 07:26 PM
Fitzgerald Kevin Joseph	Officer	Feb 17 '26	Proposed Sale	331.96	2,041	677,532		Feb 17 04:10 PM
Garg Pushkal	EVP Chief R&D	Jan 12 '26	Sale	362.87	1,510	547,929	22,511	Jan 14 04:23 PM
Greenstreet Yvonne	Chief Executive Officer	Jan 12 '26	Sale	362.86	9,577	3,475,157	78,411	Jan 14 04:23 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Jan 12 '26	Sale	362.87	2,780	1,008,766	57,465	Jan 14 04:22 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Jan 12 '26	Sale	362.87	1,510	547,927	29,728	Jan 14 04:22 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Jan 13 '26	Sale	370.33	2,290	848,065	21,264	Jan 14 04:21 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Jan 12 '26	Sale	362.87	1,510	547,927	23,554	Jan 14 04:21 PM
Fitzgerald Kevin Joseph	Officer	Jan 13 '26	Proposed Sale	369.10	2,290	845,239		Jan 13 04:32 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 26 '25	Option Exercise	106.40	4,697	499,756	70,106	Dec 01 04:10 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Nov 17 '25	Option Exercise	119.13	8,161	972,220	33,392	Nov 19 04:05 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Nov 17 '25	Sale	452.18	12,128	5,483,990	21,264	Nov 19 04:05 PM
Fitzgerald Kevin Joseph	Officer	Nov 17 '25	Proposed Sale	449.00	12,128	5,445,472		Nov 17 04:04 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 12 '25	Option Exercise	115.94	15,650	1,814,393	81,059	Nov 14 04:13 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 13 '25	Option Exercise	119.13	10,000	1,191,300	75,409	Nov 14 04:13 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 12 '25	Sale	453.69	15,650	7,100,322	65,409	Nov 14 04:13 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 13 '25	Sale	451.27	10,000	4,512,682	65,409	Nov 14 04:13 PM
Greenstreet Yvonne	Officer	Nov 12 '25	Proposed Sale	453.10	25,650	11,621,956		Nov 12 04:03 PM

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.

M.D.Dr. Yvonne L. Greenstreet M.B.A.

Co-FounderDr. Phillip A. Sharp Ph.D.

CFO & Executive VPMr. Jeffrey V. Poulton M.B.A.

Chief Legal OfficerMr. Bryan Andrew Supran J.D.

Executive VP & Chief Research & Development OfficerDr. Pushkal P. Garg M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALNY

Alnylam Pharmaceuticals Inc

Upgrade your Finviz experience